专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2019081714A1 PODOPLANIN POSITIVE MACROPHAGES 审中-公开
公开(公告)号：WO2019081714A1
公开(公告)日：2019-05-02
申请号：PCT/EP2018/079425
申请日：2018-10-26
申请人： VIB VZW , KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D
发明人： MAZZONE, Massimiliano , BIENIASZ-KRZYWIEC, Pawel
IPC分类号： G01N33/50 , A61K39/00 , G01N33/574
CPC分类号： G01N33/5055 , G01N33/5011 , G01N33/57492 , G01N2800/56
摘要： The invention relates to the field of tumor metastasis and peritumoral lymphangiogenesis. More specifically, podoplanin present on a subset of tumor-associated macrophages was identified as target for treating or inhibiting tumor metastasis and peritumoral lymphangiogenesis, and podoplanin-positive macrophages were identified as biomarker for lymphatic metastasis. The invention further relates to screening methods for identifying compounds capable of neutralizing podoplanin-positive macrophages, and to methods and kits for tumor analysis or for lymph vessel analysis.

2. 发明申请

WO2019018694A1 CANCER DIAGNOSTIC AND TREATMENT 审中-公开
公开(公告)号：WO2019018694A1
公开(公告)日：2019-01-24
申请号：PCT/US2018/042966
申请日：2018-07-19
申请人： DANA-FARBER CANCER INSTITUTE, INC.
发明人： MEYERSON, Matthew , BULLMAN, Susan
IPC分类号： A61K38/16 , A61K39/395 , A61K45/06
CPC分类号： A61K45/06 , A61P35/00 , C12Q1/18 , C40B30/06 , G01N33/5011 , G01N33/5091 , G01N33/57419 , G01N2500/10 , G01N2800/52
摘要： Bacterial species and the associated microbiome persist in tumors and metastases. Antibiotic treatment selectively reduces microbiome-induced tumor growth and can advantageously be included in treatment regimens. Accordingly, the present invention disclosure relates to, for example, the diagnosing cancer in a subject and providing identifying an effective treatment regimen for the subject.

3. 发明申请

WO2018228997A1 IMMUNE CELL MODULATION THROUGH CARDIOLIPIN SYNTHESIS 审中-公开
公开(公告)号：WO2018228997A1
公开(公告)日：2018-12-20
申请号：PCT/EP2018/065364
申请日：2018-06-11
申请人： MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
发明人： PEARCE, Erika , CORRADO, Mauro
IPC分类号： G01N33/50
CPC分类号： G01N33/5011 , G01N33/505
摘要： The present invention relates to a method for determining whether a compound has the capability of inhibiting cardiolipin synthesis, comprising (a) contacting a sample comprising T cells and/or M2 macrophages with the compound; (b) culturing the sample in the presence of the compound for at least 48h, preferably at least 60h and most preferably at least 72h; and (c) assaying in the sample the mitochondrial function of the T cells and/or M2 macrophages, wherein a reduction of the mitochondrial function as compared to a control sample not contacted with the compound indicates that the compound has the capability of inhibiting cardiolipin synthesis.

4. 发明申请

WO2018187181A1 MICROFLUIDIC SYSTEM FOR EVALUATION OF CHEMOTHERAPEUTIC AND IMMUNOTHERAPEUTIC DRUGS 审中-公开
公开(公告)号：WO2018187181A1
公开(公告)日：2018-10-11
申请号：PCT/US2018/025497
申请日：2018-03-30
申请人： THE CHARLES STARK DRAPER LABORATORY, INC.
发明人： BORENSTEIN, Jeffrey T. , GIMBEL, Alla A. , SANTOS, Jose A. , DOTY, Daniel T. , MOORE, Nathan F. , KRATCHMAN, Louis B. , TRUSLOW, James
IPC分类号： B01L3/00
CPC分类号： B01L3/50273 , B01L3/502746 , B01L3/502761 , B01L2200/027 , B01L2200/0647 , B01L2300/0864 , B01L2400/04 , B01L2400/086 , C12Q1/24 , G01N33/5011
摘要： Systems and methods for conducting assays on tissue fragment samples including providing a suspension maintaining pump, and a plurality of fluid reservoirs, wherein the fluid reservoirs are configured to hold a volume of fluid. The fluid reservoirs are fluidically coupled to a microfluidic assay chip, wherein the microfluidic assay chip includes a plurality of parallel assay channels, a first inlet port for introduction of a tissue fragment sample into the microfluidic assay ship, and a second inlet port coupled to the fluid reservoir. Each channel of the microfluidic assay chip also includes a retention barrier configured to trap the tissue fragment sample such that the fluid perfuses through the tissue sample, as well as an outlet port fluidically coupled to a waste receptacle.

5. 发明申请

WO2018090375A1 EPITHELIAL TUMOR CELL CULTURES 审中-公开
公开(公告)号：WO2018090375A1
公开(公告)日：2018-05-24
申请号：PCT/CN2016/106619
申请日：2016-11-21
申请人： BEIJING PERCANS ONCOLOGY CO. LTD.
发明人： ZHANG, Yihong , YANG, Zhen
IPC分类号： C12N5/00 , C12N5/02
CPC分类号： G01N33/5011 , C12N5/0693 , C12N2501/727 , C12N2502/1323
摘要： Provided are a cell culture medium and a method of culturing or expanding human epithelial tumor cells from cancer-tissue originated spheroids (CTOSs). Also provided is a method of testing responsiveness of a human patient to one or more therapeutic agents.

6. 发明申请

WO2018013855A2 IL-15/IL-15 RECEPTOR ALPHA TREATMENT REGIMENS AND USE WITH THERAPEUTIC VACCINES 审中-公开
标题翻译： IL-15 / IL-15受体α治疗方案及其与治疗性疫苗的应用
公开(公告)号：WO2018013855A2
公开(公告)日：2018-01-18
申请号：PCT/US2017/042002
申请日：2017-07-13
申请人： THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
发明人： FELBER, Barbara K. , PAVLAKIS, George N. , VALENTIN, Antonio
IPC分类号： A61K38/20
CPC分类号： A61K38/2086 , A61K39/12 , A61K39/39 , A61K2039/55527 , A61P31/14 , A61P31/18 , C12N2740/15034 , C12N2740/16234 , G01N33/5011 , G01N33/57492 , G01N33/6869 , G01N2333/521 , G01N2333/54 , G01N2333/5443 , G01N2333/55
摘要： The invention provides methods and dose escalation regimens for administering IL-15 to a patient in need thereof.
摘要翻译：本发明提供了将IL-15给予有需要的患者的方法和剂量增加方案。

7. 发明申请

WO2017117386A8 METHODS OF TREATING CANCER USING NETWORK BRAKES 审中-公开
标题翻译：使用网络制动器治疗癌症的方法
公开(公告)号：WO2017117386A8
公开(公告)日：2017-08-03
申请号：PCT/US2016069198
申请日：2016-12-29
申请人： ICAHN SCHOOL MED MOUNT SINAI
发明人： CAGAN ROSS , DAS TIRTHA KAMAL
IPC分类号： A61K31/00 , A61K31/33 , A61K31/395 , A61P35/00 , C40B30/00
CPC分类号： A61K31/69 , A61K31/167 , A61K31/18 , A61K31/366 , A61K31/4045 , A61K31/436 , A61K31/437 , A61K31/44 , A61K31/4406 , A61K31/4545 , A61K31/4745 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/704 , A61K45/06 , G01N33/5011 , G01N33/5023 , G01N2333/91205 , G01N2440/14 , A61K2300/00
摘要： The invention relates to improved methods of treating a cancer in a patient in need thereof using combination drug regimens that can improve therapeutic efficacy of kinase inhibitor(s). Such combination drug regimens may also reduce side effects of kinase inhibitor(s) and/or prevent or reduce cancer resistance to the kinase inhibitor(s).
摘要翻译：本发明涉及使用可改善激酶抑制剂的治疗功效的组合药物疗法治疗有需要的患者的癌症的改进方法。这种组合药物疗法还可以减少激酶抑制剂的副作用和/或预防或减少癌症对激酶抑制剂的抗性。

8. 发明申请

WO2017087810A1 METHOD FOR SCREENING INHIBITORS TARGETING ANTI-APOPTOTIC SURVIVAL PATHWAYS 审中-公开
标题翻译：筛选靶向抗凋亡存活途径的抑制剂的方法
公开(公告)号：WO2017087810A1
公开(公告)日：2017-05-26
申请号：PCT/US2016/062789
申请日：2016-11-18
申请人： MEMORIAL SLOAN-KETTERING CANCER CENTER
发明人： CHENG, Emily, H. , HSIEH, James
IPC分类号： G01N33/50 , G01N33/574
CPC分类号： G01N33/5011 , A61K31/00 , G01N2510/00
摘要： A method of identifying inhibitors of the anti-apoptotic survival pathway in cancer cells is disclosed. The method comprises the steps of (a) exposing cultured wild-type cells to a candidate inhibitor at a predetermined concentration for a predetermined period of time and determining cell viability after the exposure to the candidate inhibitor; (b) exposing two or more cell lines of specifically MCL-1 or BCL-2 or BCL-X L addicted cells to the candidate inhibitor at the predetermined concentration for the predetermined period of time and determining cell viability after the exposure to the candidate inhibitor; and (c) identifying the candidate inhibitor as a MCL-1 or BCL-2 or BCL-X L inhibitor if the cell viability in step (a) is significantly higher than the cell viability in step (b). The disclosed method provides a way to identify inhibitors which selectively inhibit specific members of the BCL-2 family ( e.g ., MCL-1) by screening two or more cell lines with addictions to different and specific members of the BCL-2 family of proteins.
摘要翻译：公开了一种鉴定癌细胞中抗凋亡存活途径抑制剂的方法。该方法包括以下步骤：（a）将培养的野生型细胞暴露于预定浓度的候选抑制剂达预定时间段，并测定暴露于候选抑制剂后的细胞活力; （b）将特定MCL-1或BCL-2或BCL-XL嗜中性细胞的两种或更多种细胞系暴露于预定浓度的候选抑制剂达预定时间段并测定细胞活力暴露于候选抑制剂后; 和（c）如果步骤（a）中的细胞活力显着高于步骤（b）中的细胞活力，则鉴定候选抑制剂为MCL-1或BCL-2或BCL-XL抑制剂）。所公开的方法提供了一种通过筛选两种或更多种细胞系选择性抑制BCL-2家族的特定成员（例如，MCL-1）的抑制剂的方法，所述细胞系对不同的和特定成员 BCL-2家族蛋白质。

9. 发明申请

WO2017075585A1 COMPOSITIONS AND METHODS RELATING TO TUMOR ANALYSIS 审中-公开
标题翻译：与肿瘤分析相关的组合物和方法
公开(公告)号：WO2017075585A1
公开(公告)日：2017-05-04
申请号：PCT/US2016/059711
申请日：2016-10-31
申请人： THE JACKSON LABORATORY
发明人： WILES, Michael, V. , HOSUR, Vishnu , SHULTZ, Leonard, D.
IPC分类号： A01K67/027 , C12N9/64 , G01N33/50 , A61K49/00
CPC分类号： A01K67/0275 , A01K67/0278 , A01K2207/12 , A01K2217/072 , A01K2217/15 , A01K2227/105 , A01K2267/0331 , A61K49/0008 , C12N9/6424 , G01N33/5011 , G01N33/5088
摘要： A genetically modified NOD.Cg -Prkdc scid Il2rg tm1Wjl /Sz J mouse is provided by the present invention wherein the genome of the mouse includes a mutated Rhbdf2 gene such that the mouse expresses a mutant iRhom2 protein, wherein the mutant iRhom2 protein differs from wild-type iRhom2 protein due to one or more mutations selected from p.I156T, p.D158N and p.P159L, and wherein the mouse is characterized by hairless phenotype and increased growth of an exogenous tumor compared to a mouse of the same genetic background which express wild-type iRhom2 protein.
摘要翻译：基因修饰的NOD.Cg -Prkdc ^{scid Il2rg ^{本发明提供了一种小鼠基因组，其中小鼠的基因组包含突变的Rhbdf2基因，使得小鼠表达突变iRhom2蛋白，其中突变iRhom2蛋白由于选自p.I156T，p.D158N和p.P159L的一个或多个突变而与野生型iRhom2蛋白不同，并且其中小鼠的特征在于无毛表型和增长的生长的外源性肿瘤与表达野生型iRhom2蛋白的相同遗传背景的小鼠相比较。}}

10. 发明申请

WO2017029414A1 AN IN VITRO 3D CELL CULTURE MODEL-BASED TUMOR RELAPSE ASSAY 审中-公开
标题翻译：一种体外3D细胞培养基于模型的肿瘤相关测定
公开(公告)号：WO2017029414A1
公开(公告)日：2017-02-23
申请号：PCT/EP2016/069803
申请日：2016-08-22
申请人： INSPHERO AG
发明人： KELM, Jens M. , LICHTENBERG, Jan
IPC分类号： C12N15/10 , G01N33/50
CPC分类号： G01N33/5011 , G01N33/5088
摘要： The present invention relates to an in vitro tumor relapse assay method, which method comprises providing a 3-dimensional cell culture or tissue comprising immortalized, malignant, cancerous and/or neoplastic cells, exposing the 3-dimensional cell culture or tissue to at least one anti-cancer agent, interrupting the exposure and determining the effect of said exposure and interruption on the 3-dimensional cell culture or tissue.
摘要翻译：本发明涉及体外肿瘤复发测定方法，该方法包括提供包含永生化，恶性，癌性和/或肿瘤细胞的3维细胞培养物或组织，将3维细胞培养物或组织暴露于至少一种抗癌剂，中断暴露并确定所述暴露和中断对3维细胞培养物或组织的影响。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式